论文部分内容阅读
目的研究新住院晚期肿瘤患者营养风险发生率,为临床进行营养支持提供科学依据。方法采用NRS2002对312例新住院肿瘤患者进行营养风险评估,根据患者疾病严重程度、营养状况受损情况(包括体重指数、近期体重变化和进食情况)以及年龄等评定营养风险,当NRS2002评分≥3分时表示有营养风险,NRS2002评分<3分表示无营养风险。结果在312例病人中,NRS2002评分≥3分者126例,占全部病例数的40.4%;在未经过抗肿瘤治疗的239例患者中,NRS2002评分≥3分者89例(37.2%),而曾经接受过抗肿瘤治疗的73例患者中,NRS2002评分≥3分者为37例(50.7%),两者比较差异有显著性(χ2=4.07,P<0.05);NRS2002评分≥3分的患者在食管癌中比例为56.2%,胃肠癌为55.6%,原发性肝癌为60.0%。结论晚期肿瘤患者存在较高营养风险,抗肿瘤治疗会进一步加剧患者的营养风险,消化系统肿瘤患者营养风险更高,对于该类患者尤其需要加强营养支持治疗。
Objective To study the incidence of nutritional risk in newly hospitalized patients with advanced cancer and provide a scientific basis for clinical nutritional support. Methods A total of 312 new inpatients with oncology were enrolled in this study. The nutritional risk was assessed by NRS2002. Nutritional risk was assessed according to the patient’s severity of disease, impaired nutritional status (including body mass index, recent body weight changes, food intake) and age. When the NRS2002 score was ≥3 Timesharing indicates a nutritional risk, and NRS2002 score <3 indicates no nutritional risk. Results Of the 312 patients, NRS2002 scores ≥3 points were 126 cases, accounting for 40.4% of the total number of cases; in 239 cases without anti-tumor therapy, 89 cases (37.2%) of NRS2002 score ≥ 3 points, and Of the 73 patients who had been treated with anti-cancer therapy, 37 (50.7%) had NRS2002 score ≥3, which was significantly different between the two groups (χ2 = 4.07, P <0.05); those with NRS2002 score ≥3 In esophageal cancer was 56.2%, gastrointestinal cancer was 55.6%, primary liver cancer was 60.0%. Conclusions There is a high nutritional risk in patients with advanced cancer. Anti-tumor therapy will further aggravate the nutritional risk of patients, and patients with digestive system tumors have a higher nutritional risk. In particular, nutritional supportive therapy should be strengthened for these patients.